Candriam SCA’s Theravance Biopharma TBPH Stock Holding History

Candriam SCA’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-44,489	Closed	-$444K	–	856
2023 Q1	$444K	Sell	44,489 -38,713	-47%	-$409K	﹤0.01%	792
2022 Q4	$933K	Sell	83,202 -19,626	-19%	-$206K	0.01%	709
2022 Q3	$1.04M	Buy	+102,828	New	+$964K	0.01%	697
2021 Q3	–	Sell	-475,696	Closed	-$6.91M	–	908
2021 Q2	$6.91M	Buy	+475,696	New	+$8.93M	0.05%	342
2020 Q2	–	Sell	-277,700	Closed	-$7.03M	–	868
2020 Q1	$7.03M	Hold	277,700	–	–	0.08%	278
2019 Q4	$7.19M	Sell	277,700 -2,000	-0.7%	-$38.9K	0.08%	283
2019 Q3	$5.45M	Hold	279,700	–	–	0.07%	299
2019 Q2	$4.55M	Hold	279,700	–	–	0.06%	352
2019 Q1	$6.34M	Hold	279,700	–	–	0.08%	271
2018 Q4	$7.16M	Buy	279,700 +25,000	+10%	+$675K	0.11%	217
2018 Q3	$8.32M	Buy	+254,700	New	+$6.94M	0.11%	219
2017 Q4	–	Sell	-20,000	Closed	-$685K	–	776
2017 Q3	$685K	Sell	20,000 -10,000	-33%	-$327K	0.01%	624
2017 Q2	$1.2M	Sell	30,000 -40,000	-57%	-$1.54M	0.02%	553
2017 Q1	$2.58M	Sell	70,000 -5,000	-7%	-$160K	0.05%	391
2016 Q4	$2.39M	Buy	+75,000	New	+$2.33M	0.05%	334

Other funds holding TBPH

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ICM

Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Candriam SCA's TBPH Position: Q2 2023 in Review

Candriam SCA sold out of Theravance Biopharma (TBPH) in Q2 2023, closing a stake of 44,489 shares — an estimated $444K sold.

Candriam SCA first reported a position in TBPH in Q4 2016 and held it in 15 quarters. The position peaked at $8.32M in Q3 2018. 119 funds tracked by Wall St. Rank hold TBPH as of Q2 2023.

Candriam SCA reported no remaining Theravance Biopharma position as of Q2 2023 after selling out during the quarter.
Candriam SCA sold 44,489 Theravance Biopharma shares in Q2 2023, an estimated $444K.
Candriam SCA first reported a position in Theravance Biopharma in Q4 2016 and held it in 15 quarters.
Candriam SCA's Theravance Biopharma position peaked at $8.32M in Q3 2018.
119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2023.

Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.